1 Meet AZN Management: ESC 2025 Conference call and webcast for investors and analysts 31 August 2025 Forward-looking statements This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statemen ...

Summary of Zhejiang Medicine Co. Ltd. Conference Call Company Overview - **Company**: Zhejiang Medicine Co. Ltd. - **Industry**: China Healthcare - **Ticker**: 600216.SS - **Market Cap**: Rmb15,078.5 million - **Current Share Price**: Rmb15.68 (as of August 27, 2025) - **Price Target**: Rmb18.00, representing a 15% upside potential Key Financial Highlights - **1H25 Revenue**: Rmb4,323 million, a decrease of 1.9% YoY - **1H25 Earnings**: Rmb673 million, an increase of 113.5% YoY - **2Q25 Revenue**: Rmb2,067 million, a decrease of 4.1% YoY - **2Q25 Earnings**: Rmb264 million, an increase of 28.5% YoY - **Nutrition Segment Revenue**: Increased by 0.6% YoY, with gross margin expanding by 15.4 percentage points to 55.0% [9][2][3] - **Formulations Segment Revenue**: Declined by 5.2% YoY to Rmb2,223 million, with gross margin contracting by 5.8 percentage points to 26.6% [3] Industry Dynamics - **Vitamin Prices**: The company continues to benefit from elevated vitamin prices due to a global supply disruption caused by a fire at BASF's Ludwigshafen plant in July 2024. This incident led to a significant increase in Chinese export prices for vitamins A and E, which rose by 9% and 76% YoY, respectively [2][9]. - **Export Tonnage**: Despite the price increases, export tonnage for vitamins A and E declined by 5% and 16% YoY, indicating potential supply chain challenges [2]. Risks and Opportunities - **Upside Risks**: - Prolonged global supply shortages could continue to benefit the company - Strong clinical data from oncology biologics and new product launches, such as next-generation antibiotics [11]. - **Downside Risks**: - Full resumption of European supply for vitamins could lead to price competition - Price cuts on antibiotics in China by the government could impact margins [11]. Valuation Metrics - **P/E Ratio**: Expected to be 13.1 for FY25 - **P/BV Ratio**: 1.4 - **ROE**: 12.1% for FY25 - **EV/EBITDA**: 6.5 for FY25 - **Free Cash Flow Yield**: 5.6% for FY25 [6]. Conclusion Zhejiang Medicine Co. Ltd. is navigating a complex landscape characterized by fluctuating vitamin prices and supply chain disruptions. While the company has shown strong earnings growth, particularly in its nutrition segment, it faces challenges in its formulations segment. The outlook remains cautiously optimistic, with potential upside from ongoing supply shortages and new product developments, but risks from competitive pricing and regulatory changes persist.

August 28, 2025 07:59 AM GMT Japan Quantitative Strategy | Japan Investment Opportunities in Japanese Equities Amid Declining Tariff Uncertainty The July 22 announcement of a 15% reciprocal tariff agreement significantly reduced trade-related uncertainty. First quarter earnings also exceeded expectations despite concerns. Amid this decline in uncertainty, we screened Japanese equities for names that are likely to benefit. Key Takeaways | M August 28, 2025 07:59 AM GMT | | Idea | | --- | --- | --- | | Japan ...

-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action --DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 31, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted in vitro data assessing the effects of EPA on lipoprotein(a) [Lp(a)] oxidation and on cellular stress and inflammatory protein expression in endothelial cells and preliminary data showcasing the potential anti-inflammatory mechanism of icosapent ethyl (IPE) via modulation of nod-like recepto ...

Core Viewpoint - The article identifies Pfizer, Summit Therapeutics, and Vertex Pharmaceuticals as strong investment opportunities in the pharmaceutical sector, highlighting their growth potential and current market conditions. Group 1: Pfizer - Pfizer is considered a top stock in healthcare due to its low valuation, high yield, and growth prospects, appealing to both dividend and growth investors [3][7] - Despite facing challenges this year related to tariffs and healthcare reform, Pfizer's underlying financials remain solid, with an adjusted EPS guidance increase to between $2.90 and $3.10 from a previous forecast of $2.80 to $3.00 [4] - The company has seen strong growth across major segments, including primary care (12%), specialty care (7%), and oncology (11%), and currently offers a dividend yield of around 6.7% [5] Group 2: Summit Therapeutics - Summit Therapeutics has experienced a significant stock increase of nearly 2,000% over three years, now holding a market cap of $18 billion [8] - The leading candidate, ivonescimab, has shown promising results in clinical trials for non-small cell lung cancer, potentially challenging the market leader, Keytruda [9][10] - Analysts project ivonescimab could generate approximately $4.4 billion in sales by 2030, indicating substantial future growth potential [11] Group 3: Vertex Pharmaceuticals - Vertex Pharmaceuticals' stock has declined over 20% due to recent pipeline setbacks, but it is viewed as a buying opportunity [13] - The company has three new products expected to drive significant sales growth, including Alyftrek for cystic fibrosis and Casgevy for rare blood disorders [14] - Vertex's new pain medication, Journavx, is gaining traction, and the company is investing in its sales and marketing efforts [15] - Vertex's PEG ratio is notably low at 0.58, suggesting it is undervalued relative to its growth prospects [17]

Core Viewpoint - The article emphasizes the importance of holding high-yield dividend stocks for the long term, highlighting five specific companies that demonstrate sustainability in their dividends and growth potential. Group 1: AbbVie - AbbVie has successfully navigated the patent cliff of its leading drug Humira, which previously accounted for over 60% of its sales, and continues to grow despite declining sales from this drug [3][4] - The company has invested in research and development and made strategic acquisitions, positioning itself for long-term success [4] - AbbVie is recognized as a Dividend King, having increased its dividend for 53 consecutive years, with a payout increase of 310% since its spin-off from Abbott Labs in 2013, currently yielding 3.16% [5] Group 2: Enbridge - Enbridge operates with a low-risk, utility-like business model, transporting 30% of North America's crude oil and 20% of the U.S. natural gas, making it a stable investment [7][8] - The company is the largest natural gas utility in North America and is investing in renewable energy, projecting $50 billion in growth opportunities through the end of the decade [8] - Enbridge has a forward dividend yield of 5.71% and has increased its dividend for 30 consecutive years [9] Group 3: Enterprise Products Partners - Enterprise Products Partners is a midstream energy leader with over 50,000 miles of pipeline, transporting various energy products [10] - Unlike Enbridge, it does not operate a natural gas utility and is structured as a limited partnership, which may involve tax complexities [11] - The company offers a high distribution yield of 6.82% and has increased its distribution for 27 consecutive years [11] Group 4: Realty Income - Realty Income has provided positive operational returns every year since its NYSE listing in 1994, supported by a diversified property portfolio with 1,630 clients across 91 industries [12][13] - The company employs a triple-net-lease business model, transferring most costs to tenants, and has significant growth opportunities in Europe [13] - Realty Income currently yields 5.55% and has increased its payout for 30 consecutive years [14] Group 5: Verizon Communications - Verizon is one of the largest wireless providers globally, benefiting from high entry barriers in the wireless network market [15] - Despite past performance challenges, the company is currently generating industry-leading wireless service revenue and has potential growth with the rollout of 6G networks by the end of the decade [16] - Verizon's dividend yield is 6.17%, and it has increased its dividend for 18 consecutive years, with expectations for continued growth [17]

Group 1 - The core point of the article is that China Resources Double Crane Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Anhui Double Crane Pharmaceutical Co., Ltd., has received the approval notice for the supplementary application of potassium chloride injection from the National Medical Products Administration [1]

Core Insights - Novo Nordisk presented data from the STEER real-world study at the ESC Congress 2025, highlighting the cardiovascular benefits of Wegovy (semaglutide 2.4 mg) compared to tirzepatide in patients with obesity and established cardiovascular disease (CVD) without diabetes [1][4]. Group 1: Study Findings - Wegovy demonstrated a significant 57% greater risk reduction for major adverse cardiovascular events (MACE) such as heart attack, stroke, and cardiovascular-related death compared to tirzepatide in patients without treatment gaps exceeding 30 days [2][8]. - In all treated individuals, Wegovy showed a 29% risk reduction for heart attack, stroke, and death from any cause compared to tirzepatide over an average follow-up of 8.3 months for Wegovy and 8.6 months for tirzepatide [3][8]. - The STEER study adds to the evidence that the heart-protective benefits of Wegovy are specific to the semaglutide molecule and not applicable to other GLP-1 or GIP/GLP-1-based treatments [8]. Group 2: Study Design and Population - The STEER study was a retrospective, observational study evaluating the efficacy of Wegovy versus tirzepatide for preventing MACE in US adults aged 45 and older with overweight or obesity and established CVD without prior diabetes [6][7]. - The study included 10,625 individuals in each treatment group, with researchers using propensity score matching to ensure comparability between Wegovy and tirzepatide users [7]. Group 3: Context of Cardiovascular Disease and Obesity - Cardiovascular disease (CVD) is the leading cause of disability and death globally, with nearly 21 million deaths annually. Obesity significantly contributes to cardiovascular morbidity and mortality [5]. - Despite a decrease in overall cardiovascular mortality over the past two decades, obesity-related cardiovascular deaths have risen, with two-thirds of such deaths linked to CVD [5].

Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke or death from any cause, in people with overweight or obesity and cardiovascular disease (CVD) who stayed on treatment1Similarly, the study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy® users compared with tirzepatide users in all treated people, regardless of any gaps in their treatment1This study adds to gro ...

Alnylam Pharmaceuticals (ALNY) Update / Briefing August 30, 2025 01:00 PM ET Company ParticipantsPushkal Garg - Executive VP, Chief Research & Development OfficerBryan Williams - Chair - Medicine & ProfessorNeha Pagidipati - Associate Professor of MedicineSimon Fox - VP - Zilebesiran Program LeadManu Chakravarthy - Senior VP, Global Head - Cardiovascular, Renal & Metabolism Product DevelopmentEllie Merle - Executive Director - Biotech Equity ResearchPushkal GargHello, everybody, and thank you for joining us ...